Paterna BioSciences
Invest in the future of male fertility
Paterna Biosciences is accelerating transformative advances in reproductive healthcare for men.
Male infertility: a global health challenge
Addressing a critical need.
30+ Years Stagnant
Male infertility treatment options have not seen innovation in over three decades.
50% IVF failure rate
Of the 3 million in vitro fertilization procedures performed annually worldwide, 50% fail.
50% male factor
Male infertility is responsible for half of all in vitro fertilization failures.
Reach out to us to learn more.
In vitro spermatogenesis: the ‘male in vitro fertilization’ equivalent
Paterna’s breakthrough solution.
Paterna is pioneering In vitro spermatogenesis (IVS), a groundbreaking laboratory technique that creates healthy sperm cells outside of the body.
This innovative science has the potential to transform male infertility treatment and give hope to millions of couples worldwide.
Help us make global fertility history.
New treatment to make parenthood possible for millions of couples.
Be at the forefront of social impact investing in reproductive health.
First mover advantage in a vast, underserved market.
Request investor packet
World-class experts leading the charge.
Alex Pastuszak
Chief Executive Officer
Jim Hotaling
Co-founder and Chief Medical Officer
Brad Cairns
Co-founder and Chair of Scientific Advisors
Jingtao Guo
Co-founder and Bioinformatics Consultant
Kyle Orwig
Co-founder and Scientific Advisor